SYED MUHAMMAD RAZA, SAİMA ZAİNAB, ALİ REZA SHAMSAEEFAR, SAMAN NİKEGHBALİAN, SEYED ALİ MALEK HOSSEİNİ
Experimental and Clinical Transplantation - 2018;16(2):177-181
Objectives: Budd-Chiari syndrome can lead to fulminant hepatic failure and cirrhosis. The treatment depends on the severity of disease. Liver transplant is a successful treatment option for those with advanced-stage disease. Material and Methods: In this retrospective study, we analyzed all liver transplants conducted for Budd- Chiari syndrome at the organ transplant unit of Shiraz University of Medical Sciences, Iran, from 1993 to January 2016. Overall, 3201 liver transplant pro - cedures were performed. Among these, 68 presented with Budd-Chiari syndrome. Results: The median age was 31 years among 27 male and 41 female patients. Five patients received pre - transplant interventions, with 2 treated with inferior vena cava stenting and 3 having transjugular intra - hepatic portosystemic shunts. Sixty-five patients with Budd-Chiari syndrome received deceased-donor grafts and 3 received living-donor grafts. Among the Budd-Chiari transplant patients, 6 patients died. Five deaths occurred in the early posttransplant period, and 1 patient retransplanted after 2 years for recur - rence of disease died due to graft failure. The five-year survival rate was 89% among patients with Budd- Chiari syndrome. Conclusions: Liver transplant along with post - transplant anticoagulation therapy can improve the survival of patients with advanced-stage Budd-Chiari syndrome.
